NVS | Novartis AG Stock Overview

(Stock Exchange: NYSE)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	0.51
Implied Volatility	25.15%
IV Rank	17.82%
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	1996-11-07

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	14.56
EPS	N/A
1YR Price Target	117.00
Dividend Yield	3.51%
Dividend Per Share	N/A
Dividend ExDate	2023-03-09
Dividend PayDate	2023-03-20
Employees	76,057
Country	Switzerland
Website	NVS

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.

NVS's peers: AMRN, AZN, BIIB, GRFS, GSK, RHHBY, BMY, SNY, MRK, BAYRY, GILD, JNJ, ABBV, LLY, PFE, OGN, SCLX

*Chart delayed

Analyzing fundamentals for NVS we got that it has strong fundamentals where Valuation is considered to be significantly undervalued, Profitability is very wealthy, Growth is good and Health is strong. For more detailed analysis please see NVS Fundamentals page.

Watching at NVS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NVS Technicals page.